DiaMedica Therapeutics Inc. (NASDAQ: DMAC) reported Q2 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19).

For earnings history and earnings-related data on DiaMedica Therapeutics Inc. (DMAC) click here.